Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGON NASDAQ:PTCT NASDAQ:XENE NASDAQ:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$73.52+6.1%$65.48$23.65▼$77.00$6.11B0.22932,610 shs1.14 million shsPTCTPTC Therapeutics$75.80-1.3%$77.30$43.17▼$90.87$6.37B0.531.72 million shs1.85 million shsXENEXenon Pharmaceuticals$65.78+0.6%$58.54$30.00▼$72.66$6.32B0.611.35 million shs517,135 shsZYMEZymeworks$23.00+0.6%$24.44$11.51▼$29.75$1.67B1.13528,464 shs259,300 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology+6.06%+4.74%+2.17%+12.16%+181.69%PTCTPTC Therapeutics-1.33%-2.83%-10.22%+7.88%+69.42%XENEXenon Pharmaceuticals+0.55%-0.39%+10.11%+20.63%+117.10%ZYMEZymeworks+0.61%-3.20%-4.76%-17.68%+72.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$73.52+6.1%$65.48$23.65▼$77.00$6.11B0.22932,610 shs1.14 million shsPTCTPTC Therapeutics$75.80-1.3%$77.30$43.17▼$90.87$6.37B0.531.72 million shs1.85 million shsXENEXenon Pharmaceuticals$65.78+0.6%$58.54$30.00▼$72.66$6.32B0.611.35 million shs517,135 shsZYMEZymeworks$23.00+0.6%$24.44$11.51▼$29.75$1.67B1.13528,464 shs259,300 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology+6.06%+4.74%+2.17%+12.16%+181.69%PTCTPTC Therapeutics-1.33%-2.83%-10.22%+7.88%+69.42%XENEXenon Pharmaceuticals+0.55%-0.39%+10.11%+20.63%+117.10%ZYMEZymeworks+0.61%-3.20%-4.76%-17.68%+72.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGONCG Oncology 2.71Moderate Buy$81.7311.16% UpsidePTCTPTC Therapeutics 2.80Moderate Buy$92.2921.75% UpsideXENEXenon Pharmaceuticals 3.00Buy$77.2017.36% UpsideZYMEZymeworks 2.82Moderate Buy$37.3362.32% UpsideCurrent Analyst Ratings BreakdownLatest ZYME, PTCT, XENE, and CGON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026PTCTPTC Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$95.00 ➝ $93.007/17/2026CGONCG Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026ZYMEZymeworks Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/16/2026PTCTPTC Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$124.00 ➝ $130.007/7/2026PTCTPTC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$82.00 ➝ $85.007/7/2026PTCTPTC Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/7/2026ZYMEZymeworks Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $31.007/6/2026XENEXenon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/30/2026ZYMEZymeworks Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$34.00 ➝ $37.006/30/2026ZYMEZymeworks CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/9/2026ZYMEZymeworks Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$28.00(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGONCG Oncology$4.04M1,605.07N/AN/A$9.33 per share7.88PTCTPTC Therapeutics$1.73B3.63$8.66 per share8.75($2.56) per share-29.61XENEXenon Pharmaceuticals$7.50M847.86N/AN/A$7.53 per share8.74ZYMEZymeworks$105.96M15.85N/AN/A$3.59 per share6.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGONCG Oncology-$160.99M-$2.33N/AN/AN/AN/A-23.33%-22.24%8/7/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A35.596.69-22.58%-362.45%-6.76%7/30/2026 (Estimated)XENEXenon Pharmaceuticals-$345.91M-$4.70N/AN/AN/AN/A-49.23%-46.42%8/10/2026 (Estimated)ZYMEZymeworks-$81.13M-$1.37N/AN/AN/A-126.92%-37.97%-25.31%8/6/2026 (Estimated)Latest ZYME, PTCT, XENE, and CGON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026XENEXenon Pharmaceuticals-$1.16N/AN/AN/A$1.67 millionN/A8/7/2026Q2 2026CGONCG Oncology-$0.70N/AN/AN/A$0.36 millionN/A8/6/2026Q2 2026ZYMEZymeworks-$0.4483N/AN/AN/A$17.19 millionN/A7/30/2026Q2 2026PTCTPTC Therapeutics$0.22N/AN/AN/A$298.63 millionN/A5/8/2026Q1 2026CGONCG Oncology-$0.58-$0.71-$0.13-$0.71$0.45 million$1.08 million5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/7/2026Q1 2026XENEXenon Pharmaceuticals-$1.17-$1.17N/A-$1.17$1.36 millionN/A5/7/2026Q1 2026ZYMEZymeworks-$0.10-$0.59-$0.49-$0.59$24.38 million$2.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGONCG OncologyN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGONCG OncologyN/A31.3031.25PTCTPTC TherapeuticsN/A2.442.36XENEXenon PharmaceuticalsN/A27.7927.79ZYMEZymeworksN/A10.8210.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGONCG Oncology26.56%PTCTPTC TherapeuticsN/AXENEXenon Pharmaceuticals95.45%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipCGONCG Oncology4.80%PTCTPTC Therapeutics5.50%XENEXenon Pharmaceuticals2.91%ZYMEZymeworks33.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGONCG Oncology6188.20 million83.97 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableXENEXenon Pharmaceuticals21096.67 million93.85 millionOptionableZYMEZymeworks46073.02 million48.55 millionN/AZYME, PTCT, XENE, and CGON HeadlinesRecent News About These CompaniesSummitTX Capital L.P. Purchases 97,159 Shares of Zymeworks Inc. $ZYMEJuly 27 at 6:31 AM | marketbeat.comZymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026July 16, 2026 | financialpost.comFZymeworks Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026July 16, 2026 | quiverquant.comQZymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026July 16, 2026 | globenewswire.comTruist Remains Bullish on Zymeworks (ZYME) – Here’s WhyJuly 15, 2026 | finance.yahoo.comHillsdale Investment Management Inc. Has $8.65 Million Stock Position in Zymeworks Inc. $ZYMEJuly 14, 2026 | marketbeat.comPictet Asset Management Holding SA Has $232,000 Stock Position in Zymeworks Inc. $ZYMEJuly 13, 2026 | marketbeat.comHere's Why Zymeworks Inc. Paid $929M For Theravance BiopharmaJuly 1, 2026 | seekingalpha.comHere's Why Zymeworks Inc. Paid $929 Million For Theravance BiopharmaJuly 1, 2026 | seekingalpha.comZymeworks to acquire Theravance Biopharma in deal worth $929mJuly 1, 2026 | pmlive.comPIs Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?June 30, 2026 | finance.yahoo.comTheravance Stock Down 3% After Zymeworks Announces BuyoutJune 30, 2026 | zacks.comZymeworks Inc. (ZYME) M&A Call - SlideshowJune 30, 2026 | seekingalpha.comZymeworks agrees to buy Theravance Biopharma for $929mJune 30, 2026 | finance.yahoo.comTheravance, after clinical setbacks, agrees to $929M buyoutJune 29, 2026 | finance.yahoo.comZymeworks offers US$929-million for COPD drug maker TheravanceJune 29, 2026 | theglobeandmail.comZymeworks to buy Theravance for $929 million in push to expand beyond cancerJune 29, 2026 | msn.comZymeworks Inc. (ZYME) M&A Call TranscriptJune 29, 2026 | seekingalpha.comPharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance BiopharmaJune 29, 2026 | pharmexec.comPWhy This Biotech Stock Is Falling After a $929 Million Buyout LifelineJune 29, 2026 | msn.comZymeworks cuts deal to buy Theravance for $929m in cashJune 29, 2026 | pharmaphorum.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZYME, PTCT, XENE, and CGON Company DescriptionsCG Oncology NASDAQ:CGON$73.52 +4.20 (+6.06%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$74.46 +0.94 (+1.27%) As of 07/27/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.PTC Therapeutics NASDAQ:PTCT$75.80 -1.02 (-1.33%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$75.79 -0.01 (-0.01%) As of 07/27/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Xenon Pharmaceuticals NASDAQ:XENE$65.78 +0.36 (+0.55%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$65.28 -0.50 (-0.77%) As of 07/27/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.Zymeworks NASDAQ:ZYME$23.00 +0.14 (+0.61%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$23.01 +0.01 (+0.04%) As of 07/27/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now AMD’s AI Bubble Could Burst Into Explosive Upside Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? A $1.5 Billion Wake-Up Call for Every AI Company on Wall Street AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear Case Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight Apple’s Earnings Setup Puts Its Record Rally and AI Patience to the Test Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
